Subscribe

Glossary

Antisynthetase syndrome

An autoimmune illness defined by one family of antibodies. It classically hits muscle, joints, and lungs. Most people never get all three. The lungs are the part that counts most.

Textbooks describe three things happening together, and that is where most of the confusion about this illness begins. In one study of 88 people, only 36.4 percent had all three. The distance between the textbook description and what turns up in a clinic is the most useful thing to know here.

Quick answerAntisynthetase syndrome is an autoimmune illness marked out by one family of antibodies rather than by one organ. It classically hits muscle, joints, and lungs together, though in one study of 88 people only 36.4 percent had all three. Lung trouble was the most common single feature there, at 90 percent.
Which antibody shows on your test changes the start of this illness more than it changes the end. One study of 828 people found survival wasn't changed by which one a person had. The first symptom does differ, and one study of 88 people looked at what came first, finding joint pain alone in 47.6 percent of anti-Jo-1 patients and lung disease alone in 50 percent of anti-EJ patients. So the route in varies while the place it leads is less different than it looks, and your own team can say which antibody you have.

What this illness is

Antisynthetase syndrome is an autoimmune illness defined by a family of antibodies rather than by one organ. That's unusual, and it explains a good deal of what follows on this page. The antibodies are aimed at enzymes inside your cells that help build proteins, and there are several of them, each with a name of its own.

Anti-Jo-1 is much the most common of that whole family by some distance. The classic description says this illness affects three things together, which are the muscles, the joints, and the lungs. That description is where most of the confusion about the illness starts, and the next section is about why.

The lungs count for the most

Every study gathered here points in one direction about which part is most serious, and that direction is the lungs. It holds whichever antibody a person turns out to have. In the Chinese study of 88 people, lung disease was the most common feature at 90 percent.

A Hungarian study followed 49 people who tested positive for anti-Jo-1, where lung disease reached 73 percent alongside myositis in 100 percent and arthritis in 88 percent. A study of 205 people followed them for a median of four years, over which 15.6 percent died and lung disease or pneumonia were the major causes. Every single person with anti-EJ antibodies in that study developed lung disease over the follow-up.

What predicts a worse outcome

Two studies looked at this directly, and they don't contradict each other. Between them they name five things worth knowing about. One study of 205 people found three independently associated with death, which were age at diagnosis, cancer, and rapidly progressive lung disease.

Joint involvement went the other way in that study and came out protective. One study of 103 people with anti-Jo-1 and lung disease found two more. Being male predicted death at a hazard ratio of 2.60, at P equals 0.04, and gas transfer at presentation predicted it at 0.94, at P equals 0.05, after adjusting for age, sex, and two lung measures.

That second finding is worth reading slowly. A hazard ratio of 0.94 per unit means better gas transfer was associated with lower risk rather than higher. It's the one number on this page that describes something measured at every lung function test you have.

Common misconceptions.

Myth. You need all three problems to have this.

Reality. Most people don't have all three of them, and one Chinese study of 88 people shows how far off the classic picture is. Only 32 of them, or 36.4 percent, had muscle, joint, and lung trouble together. Lung disease on its own reached 90 percent, so the classic description says what can happen rather than what usually does, and waiting for the full set delays the diagnosis.

Myth. It's mainly a muscle disease.

Reality. The lungs count for a great deal more than the muscles do here. In that study of 88 people, lung disease reached 90 percent while muscle trouble reached 79.5 percent. A study of 205 people followed them for four years, over which 15.6 percent died with lung disease or pneumonia as the major causes, and every person with anti-EJ antibodies developed lung disease over the follow-up.

Myth. Which antibody I have decides my outcome.

Reality. It changes the start of the illness a good deal more than it changes the finish. One study followed 828 people and found survival wasn't changed by which antibody a person had. What did differ was the opening, because in anti-Jo-1 patients joint pain alone came first in 47.6 percent, while in anti-EJ patients lung disease alone came first in 50 percent.

Myth. A negative anti-Jo-1 test rules it out.

Reality. It rules out the most common member of the family rather than the family itself. One study of 205 people found anti-Jo1 in 49.3 percent, so about half of them had something else instead. That counts in practice, because in that study diagnosis took longer without anti-Jo1, at a median of five months against three.

Myth. This is a common illness.

Reality. It isn't common, and the numbers behind that are worth seeing. One study looked at 460 people with inflammatory muscle disease and found an antisynthetase antibody in 51 of them, or 11.1 percent. So it's an uncommon subgroup of an uncommon set of illnesses, and that counts for what you read, because most of the studies here have fewer than 200 people in them.

Related terms.

References.

  1. Wang R; Zhao Y; Qi F et al. Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China. Clin Rheumatol. 2023;42:703-709. 10.1007/s10067-022-06404-8Retrospective cohort of 88 patients diagnosed with antisynthetase syndrome at one Chinese hospital between January 2015 and December 2020
  2. Tang HS; Tang IYK; Ho RTC et al. Clinical heterogeneity and prognostic factors of anti-synthetase syndrome: a multi-centred retrospective cohort study. Rheumatology (Oxford). 2025;64:212-220. 10.1093/rheumatology/kead671Multicentre retrospective longitudinal cohort of 205 patients meeting Connor's or Solomon's criteria for antisynthetase syndrome
  3. Cavagna L; Trallero-Araguás E; Meloni F et al. Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. J Clin Med. 2019;8. 10.3390/jcm8112013Retrospective analysis of 828 patients with antisynthetase syndrome from the American and European Network of Antisynthetase Syndrome collaborative cohort
  4. Zamora AC; Hoskote SS; Abascal-Bolado B et al. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome. Respir Med. 2016;118:39-45. 10.1016/j.rmed.2016.07.009Fifteen-year cohort of 103 patients identified with anti-Jo-1 positive antisynthetase syndrome and interstitial lung disease
  5. Szabó K; Bodoki L; Nagy-Vincze M et al. Effect of Genetic and Laboratory Findings on Clinical Course of Antisynthetase Syndrome in a Hungarian Cohort. Biomed Res Int. 2018;2018:6416378. 10.1155/2018/6416378Retrospective study of the clinical database of 49 anti-Jo-1 positive antisynthetase patients followed at a single Hungarian centre
  6. Noguchi E; Uruha A; Suzuki S et al. Skeletal Muscle Involvement in Antisynthetase Syndrome. JAMA Neurol. 2017;74:992-999. 10.1001/jamaneurol.2017.0934Cohort study collecting muscle biopsy and blood samples from 460 patients with idiopathic inflammatory myositis across regional referral centres in Japan between October 2010 and December 2014
  7. Zhan X; Yan W; Wang Y et al. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China. BMC Pulm Med. 2021;21:57. 10.1186/s12890-021-01399-5Retrospective cohort of 108 consecutive patients with antisynthetase syndrome-associated interstitial lung disease at one Beijing hospital
  8. Sreevilasan SK; Devarasetti P; Narahari NK et al. Clinical profile and treatment outcomes in antisynthetase syndrome: a tertiary centre experience. Rheumatol Adv Pract. 2021;5:ii10-ii18. 10.1093/rap/rkab054Prospective follow-up of 28 patients classified as antisynthetase syndrome by Connors criteria at a tertiary centre over 5 years
  9. Bozzalla-Cassione E; Zanframundo G; Biglia A et al. Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study. Clin Exp Rheumatol. 2022;40 Suppl 134:27-31. 10.55563/clinexprheumatol/bjb2gfRetrospective single-centre cohort of 60 patients with antisynthetase syndrome
  10. Muscato G; Morina G; Fagone E et al. Interstitial Lung Disease Secondary to Sjogren's Syndrome and Antisynthetase Syndrome: Converging Disease Trajectories. Medicina (Kaunas). 2025;61. 10.3390/medicina61112044Retrospective study comparing 34 patients with Sjogren's syndrome-associated interstitial lung disease against 33 with antisynthetase syndrome-associated interstitial lung disease

Free download

The First Changes to Make.

The same handout I hand my own patients: the specific food and daily-exposure changes worth making first, no guesswork required.

We'll email you the list and keep your address so we can send you something occasionally. We won't sell it or pass it on, and you can unsubscribe from any email. How we handle it.

No spam · Unsubscribe any time

This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.